A plasma metabolite score of three eicosanoids predicts incident type 2 diabetes: a prospective study in three independent cohorts.
Authors
Long, Tao
Watrous, Jeramie D
Mercader, Kysha
Lagerborg, Kim A
Andres, Allen
Salmi, Marko
Jalkanen, Sirpa
Vasan, Ramachandran S
Inouye, Michael
Havulinna, Aki S
Tuomilehto, Jaakko
Jousilahti, Pekka
Niiranen, Teemu J
Cheng, Susan
Jain, Mohit
Publication Date
2022-03Journal Title
BMJ Open Diabetes Res Care
ISSN
2052-4897
Publisher
BMJ
Volume
10
Issue
2
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Tuomisto, K., Palmu, J., Long, T., Watrous, J. D., Mercader, K., Lagerborg, K. A., Andres, A., et al. (2022). A plasma metabolite score of three eicosanoids predicts incident type 2 diabetes: a prospective study in three independent cohorts.. BMJ Open Diabetes Res Care, 10 (2) https://doi.org/10.1136/bmjdrc-2021-002519
Abstract
INTRODUCTION: Peptide markers of inflammation have been associated with the development of type 2 diabetes. The role of upstream, lipid-derived mediators of inflammation such as eicosanoids, remains less clear. The aim of this study was to examine whether eicosanoids are associated with incident type 2 diabetes. RESEARCH DESIGN & METHODS: In the FINRISK (Finnish Cardiovascular Risk Study) 2002 study, a population-based sample of Finnish men and women aged 25-74 years, we used directed, non-targeted liquid chromatography-mass spectrometry to identify 545 eicosanoids and related oxylipins in the participants' plasma samples (n=8292). We used multivariable-adjusted Cox regression to examine associations between eicosanoids and incident type 2 diabetes. The significant independent findings were replicated in the Framingham Heart Study (FHS, n=2886) and DIetary, Lifestyle and Genetic determinants of Obesity and Metabolic syndrome (DILGOM) 2007 (n=3905). Together, these three cohorts had 1070 cases of incident type 2 diabetes. RESULTS: In the FINRISK 2002 cohort, 76 eicosanoids were associated individually with incident type 2 diabetes. We identified three eicosanoids independently associated with incident type 2 diabetes using stepwise Cox regression with forward selection and a Bonferroni-corrected inclusion threshold. A three-eicosanoid risk score produced an HR of 1.56 (95% CI 1.41 to 1.72) per 1 SD increment for risk of incident diabetes. The HR for comparing the top quartile with the lowest was 2.80 (95% CI 2.53 to 3.07). In the replication analyses, the three-eicosanoid risk score was significant in FHS (HR 1.24 (95% CI 1.10 to 1.39, p<0.001)) and directionally consistent in DILGOM (HR 1.12 (95% CI 0.99 to 1.27, p=0.07)). Meta-analysis of the three cohorts yielded a pooled HR of 1.31 (95% CI 1.05 to 1.56). CONCLUSIONS: Plasma eicosanoid profiles predict incident type 2 diabetes and the clearest signals replicate in three independent cohorts. Our findings give new information on the biology underlying type 2 diabetes and suggest opportunities for early identification of people at risk.
Keywords
Genetics/Genomes/Proteomics/Metabolomics, 1506, 1879, eicosanoids, inflammation, diabetes mellitus, type 2, epidemiology
Sponsorship
Paavo Nurmi Foundation (N/A)
Emil Aaltonen Foundation (N/A)
Eli Lilly Finland (N/A)
The Future Forum, Astra Zeneca (N/A)
Academy of Finland (141136, 321351, 321356, 46558)
National Institutes of Health (K01DK116917, R01ES027595, S10OD020025)
Social Insurance Institution of Finland (N/A)
Framingham Heart Study (75N92019D00031, HHSN268201500001I, N01-HC-25195)
Aarne Koskelo Foundation (N/A)
Department of Medicine, Boston University School of Medicine (Evans Scholar award and Jay and Louis Coffman Foun)
Finnish Foundation for Cardiovascular Research (N/A)
Finnish Medical Foundation (N/A)
Identifiers
bmjdrc-2021-002519
External DOI: https://doi.org/10.1136/bmjdrc-2021-002519
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335774
Rights
Licence:
http://creativecommons.org/licenses/by-nc/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk